This page shows the latest Viaskin Peanut news and features for those working in and with pharma, biotech and healthcare.
Aimmune’s potential rival, DBV Technologies, has not had as much success with getting its peanut allergy treatment approved. ... In August, DBV announced that it had received a complete response letter (CRL) from the US Food and Drug Administration (FDA
drug. Like Palforzia, the rationale for Viaskin Peanut is to expose people with peanut allergy to small amounts of antigen over time to encourage the immune system to develop tolerance. ... Analysts at Baird have suggested that with a weaker clinical
When used in conjunction with peanut avoidance, Palforzia provides an FDA-approved treatment option to help reduce the risk of these allergic reactions in children with peanut allergy,” added Marks. ... California biotech Aimmune has been in a race to
Peanut allergies are the leading cause of death from food-induced allergic reactions in the US. ... DBV was forced to withdraw the US marketing application for its Viaskin Peanut patch product last December after the FDA expressed concerns about
Follows initial manufacturing concerns. DBV Technologies was hit hard a few months back when it was forced to pull its FDA filing for peanut allergy therapy Viaskin Peanut. ... This is an important milestone for DBV, as we are one step closer towards
for the 1.6m people with peanut allergy in the US, and presented its case at an ICER meeting yesterday. ... Aimmune is currently leading the race to bring a peanut allergy therapy to market, after its main rival DBV Technologies decided to withdraw the
More from news
Approximately 1 fully matching, plus 6 partially matching documents found.
Operating in 50+ countries, we’re a leading research, educational, and professional publisher dedicated to advancing scientific discovery. Whether you’re looking...